Sitala Bio Ltd
Clinical trials sponsored by Sitala Bio Ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill aims to slow kidney disease in IgA nephropathy patients Results expected Jul 2027 (estimated)
-
New pill aims to slow vision loss from dry macular degeneration
Disease control Recruiting nowThis study tests an oral drug called STL303 for geographic atrophy, a form of dry age-related macular degeneration that causes a blind spot in central vision. About 300 adults aged 60 and older will receive either STL303 or a placebo pill for up to 2 years. The goal is to see if …
Phase 2 • Sponsor: Sitala Bio LTD • Aim: Disease control
Last updated Sep 21, 2026 19:00 UTC
-
New pill aims to slow kidney disease in IgA nephropathy patients
Disease control Recruiting nowThis study tests an experimental drug called STL303 for people with IgA nephropathy, a kidney disease. About 15 adults will receive either STL303 or a placebo to see if the drug is safe and can reduce protein in the urine, a sign of kidney damage. Possible side effects include na…
Phase 2 • Sponsor: Sitala Bio LTD • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC